Wall Street brokerages expect Catalyst Pharmaceuticals (NASDAQ:CPRX) to announce ($0.06) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for Catalyst Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.07) and the highest is ($0.05). Catalyst Pharmaceuticals also posted earnings per share of ($0.06) during the same quarter last year. The firm is expected to report its next quarterly earnings report on Wednesday, May 9th.
On average, analysts expect that Catalyst Pharmaceuticals will report full-year earnings of ($0.36) per share for the current fiscal year, with EPS estimates ranging from ($0.58) to ($0.23). For the next year, analysts expect that the company will post earnings of ($0.11) per share, with EPS estimates ranging from ($0.23) to ($0.01). Zacks Investment Research’s EPS calculations are an average based on a survey of research firms that follow Catalyst Pharmaceuticals.
Catalyst Pharmaceuticals (NASDAQ:CPRX) last announced its earnings results on Wednesday, March 14th. The biopharmaceutical company reported ($0.06) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.06).
CPRX has been the subject of several recent research reports. HC Wainwright restated a “buy” rating and set a $6.00 target price on shares of Catalyst Pharmaceuticals in a report on Thursday, December 21st. BidaskClub cut shares of Catalyst Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, January 24th. Two equities research analysts have rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $6.25.
CPRX traded up $0.14 during trading hours on Thursday, hitting $2.62. 822,588 shares of the company’s stock were exchanged, compared to its average volume of 673,876. Catalyst Pharmaceuticals has a 1-year low of $1.62 and a 1-year high of $4.51. The stock has a market capitalization of $261.52, a price-to-earnings ratio of -12.29 and a beta of 1.62.
In other Catalyst Pharmaceuticals news, insider Patrick J. Mcenany bought 20,000 shares of Catalyst Pharmaceuticals stock in a transaction that occurred on Tuesday, April 3rd. The stock was acquired at an average price of $2.29 per share, for a total transaction of $45,800.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 9.60% of the company’s stock.
A number of hedge funds have recently made changes to their positions in CPRX. Consonance Capital Management LP lifted its stake in Catalyst Pharmaceuticals by 1,111.4% in the fourth quarter. Consonance Capital Management LP now owns 4,473,607 shares of the biopharmaceutical company’s stock valued at $17,492,000 after acquiring an additional 4,104,309 shares during the last quarter. Millennium Management LLC acquired a new stake in Catalyst Pharmaceuticals in the fourth quarter valued at $8,082,000. Emerald Advisers Inc. PA acquired a new stake in Catalyst Pharmaceuticals in the fourth quarter valued at $5,364,000. Driehaus Capital Management LLC acquired a new stake in Catalyst Pharmaceuticals in the fourth quarter valued at $4,812,000. Finally, EAM Investors LLC acquired a new stake in Catalyst Pharmaceuticals in the fourth quarter valued at $4,076,000. Hedge funds and other institutional investors own 54.66% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Brokerages Anticipate Catalyst Pharmaceuticals (CPRX) Will Announce Earnings of -$0.06 Per Share” was posted by Macon Daily and is the property of of Macon Daily. If you are accessing this piece on another website, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The correct version of this piece can be read at https://macondaily.com/2018/04/12/brokerages-anticipate-catalyst-pharmaceuticals-cprx-will-announce-earnings-of-0-06-per-share.html.
Catalyst Pharmaceuticals Company Profile
Catalyst Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. Its product candidates include Firdapse, a proprietary form of amifampridine phosphate that has completed Phase III clinical trials for the treatment of patients with lambert-eaton myasthenic syndrome; is in Phase III clinical trial to treat congenital myasthenic syndromes; and is in Phase III clinical trial for the treatment of anti-MuSK antibody positive myasthenia gravis, as well as is in Phase II clinical trial for patients with spinal muscular atrophy type 3.
Get a free copy of the Zacks research report on Catalyst Pharmaceuticals (CPRX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.